Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021
Camille N. Kotton, Camille N. Kotton, Julián Torre‐Cisneros, José María Aguado, Sophie Alain, Fausto Baldanti, Gabriele Baumann, Udo Boeken, María de la Calle, Javier Carbone, Fabio Ciceri, Patrizia Comoli, Lionel Couzi, Lara Danziger‐Isakov, Mario Fernández‐Ruiz, Corrado Girmenia, Paolo Grossi, Hans H. Hirsch, Atul Humar, Nassim Kamar, Camille N. Kotton, Camille N. Kotton, Per Ljungman, Michele Malagola, Estefanía Mira, Nicolas J. Mueller, Martina Sester, Chieh‐Lin Jerry Teng, Julián Torre‐Cisneros, Piedad Ussetti, Glen Westall, Dana G. Wolf, Marty Zamora
Abstract
The CMV Symposium in September 2021 was an international conference dedicated to cytomegalovirus (CMV) infection after solid organ or hematopoietic stem cell transplantation. This review provides an overview of the presentations given by the expert faculty, supplemented with educational clinical cases. Topics discussed include CMV epidemiology and diagnosis, the burden of CMV infection and disease, CMV-specific immunity and management of CMV in transplant settings. Major advances in the prevention and treatment of CMV in the past decade and increased understanding of CMV immunity have led to improved patient outcomes. In the future, management algorithms may be individualized based on the transplant recipient's immune profile, which will mark the start of a new era for patients with CMV.